Literature DB >> 1919295

Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury.

C McClain1, D Cohen, R Phillips, L Ott, B Young.   

Abstract

The cytokine interleukin-6 (IL-6) plays a major role in initiating the acute phase response, especially in the production of acute phase reactants such as C-reactive protein. The objectives of this study were to determine whether plasma or ventricular fluid IL-6 levels were elevated at time of admission after head injury and whether plasma IL-6 levels related temporally to clinical improvement of levels of acute phase reactants. Thirty patients with Glasgow Coma Scale (GCS) scores of 3 through 10 were observed for 15 days after head injury. Peak elevation of plasma IL-6 occurred on admission (85 +/- 12 U/ml; normal level is less than 2 U/ml) and then decreased during the hospital course to a level of 29 +/- 4 U/ml on day 15. Plasma IL-6 levels decreased significantly faster in patients with admission peak 24-hour GCS scores of 8 through 10 compared with patients with GCS score less than 8 (p less than 0.01). Patients had markedly elevated and variable ventricular fluid IL-6 levels on admission (mean 3880 +/- 2022 U/ml; normal, less than 2 U/ml). A temporal relationship was found between plasma IL-6 levels and multiple acute phase reactants thought to be mediated by IL-6. We conclude that plasma and ventricular fluid levels of IL-6 are elevated after head injury and that plasma IL-6 level is temporally related to acute phase reactants and clinical improvement. We suggest that IL-6 may play an etiologic role in many of the metabolic or nutritional sequelae of head injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919295

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  20 in total

1.  Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus.

Authors:  Jiyong Zhang; Grazyna B Sadowska; Xiaodi Chen; Seon Yeong Park; Jeong-Eun Kim; Courtney A Bodge; Erin Cummings; Yow-Pin Lim; Oleksandr Makeyev; Walter G Besio; John Gaitanis; William A Banks; Barbara S Stonestreet
Journal:  FASEB J       Date:  2015-01-21       Impact factor: 5.191

2.  Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.

Authors:  Gail D Anderson; Nancy R Temkin; Asaad B Awan; H Richard Winn; Richard H Winn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Pharmacological treatment of traumatic brain injury: a review of agents in development.

Authors:  J Hatton
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model.

Authors:  Gail D Anderson; Todd C Peterson; Cole Vonder Haar; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Michael R Hoane
Journal:  AAPS J       Date:  2015-06-12       Impact factor: 4.009

5.  Temperature-related effects of adenosine triphosphate-activated microglia on pro-inflammatory factors.

Authors:  Tomohiro Matsui; Yukari Motoki; Takafumi Inomoto; Daisuke Miura; Yukiko Kato; Hiromi Suenaga; Keisuke Hino; Junzo Nojima
Journal:  Neurocrit Care       Date:  2012-10       Impact factor: 3.210

6.  Possible role of short-term parenteral nutrition with fat emulsions for development of haemophagocytosis with multiple organ failure in a patient with traumatic brain injury.

Authors:  B Roth; P O Grände; P Nilsson-Ehle; I Eliasson
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

7.  Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome.

Authors:  Antonio Chiaretti; Orazio Genovese; Luigi Aloe; Alessia Antonelli; Marco Piastra; Giancarlo Polidori; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2004-09-29       Impact factor: 1.475

8.  Variable neuroendocrine-immune dysfunction in individuals with unfavorable outcome after severe traumatic brain injury.

Authors:  M Santarsieri; R G Kumar; P M Kochanek; S Berga; A K Wagner
Journal:  Brain Behav Immun       Date:  2014-09-16       Impact factor: 7.217

9.  Blunted IL-6 and IL-10 response to maximal aerobic exercise in patients with traumatic brain injury.

Authors:  Kyle L Timmerman; William E Amonette; Melissa M Markofski; Hayden A Ansinelli; Elizabeth A Gleason; Blake B Rasmussen; Kurt A Mossberg
Journal:  Eur J Appl Physiol       Date:  2014-09-12       Impact factor: 3.078

10.  The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia.

Authors:  Wendy Su; Gavril W Pasternak
Journal:  Synapse       Date:  2013-05-02       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.